COMMUNIQUÉS West-GlobeNewswire

Stride Autism Centers Opens New Facility in Sioux Falls to Extend Autism Support in South Dakota
13/05/2024
SIOUX FALLS, S.D., May 13, 2024 (GLOBE NEWSWIRE) -- Stride Autism Centers ("Stride"), a mission-driven provider of evidence-based therapy for children with autism, proudly announces the opening of its new center in [...]
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions
13/05/2024
Collaboration will initially focus on the role of sleep endpoints in clinical trials relating to rare epilepsy syndromes BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals announced a strategic partnership with [...]
ProSomnus Contributes Two Scientific Abstracts Accepted for Presentation at the 2024 American Academy of Dental Sleep Medicine Annual Meeting
13/05/2024
PLEASANTON, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that it has contributed two scientific abstracts that have [...]
Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024
13/05/2024
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today [...]
QHSLab, Inc. Announces Strong First Quarter 2024 Results with Significant Reduction in Operating Expenses and Positive Net Operating Income
13/05/2024
Integrated Service Program (ISP) Revenues Surge 268% in Q1 2024 Over Q1 2023 WEST PALM BEACH, FL, May 13, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. ("the Company") (OTCQB: USAQ), a leader in digital health and point-of-care [...]
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
13/05/2024
Proof-of-concept study for Imunon’s first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, [...]
Scilex Holding Company Provides Information to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock
13/05/2024
Scilex management is determined to enhance its stockholders’ value and protect their stockholder rights, and is taking steps to combat manipulative and naked short selling practices in Scilex common stock. Of the [...]
Baylor Genetics Launches RNASeq Test for Whole Genome and Whole Exome Sequencing, Reduces Turnaround Times, Introduces Four New Genetic Analysis Panels
13/05/2024
HOUSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic laboratory at the forefront of genetic testing, today announced the availability of a new RNA sequencing test, RNAseq, for Whole Exome [...]
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
13/05/2024
UK submission for national MAA review follows recently received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) concerning the authorization of ONS-5010 [...]
Safety Shot Partners with Gopuff
13/05/2024
Gopuff, a delivery service that brings thousands of products to your doorstep in minutes, will aid in turning Safety Shot into a household brand. JUPITER, FL, May 13, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: [...]
Checkpoint Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13/05/2024
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President [...]
Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024
13/05/2024
LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it [...]
Milestone Scientific Schedules First Quarter 2024 Financial Results and Business Update Conference Call
13/05/2024
ROSELAND, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that [...]
Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer
13/05/2024
JERUSALEM, May 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that [...]
Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial
13/05/2024
COPENHAGEN, Denmark, May 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 2-year results from a post-hoc analysis of the Company’s Phase 3 PaTHway Trial demonstrating significant and [...]
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
13/05/2024
Company to disclose new programs from existing unnamed pre-clinical pipeline CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company [...]
TransCode Therapeutics Open Letter to Shareholders
13/05/2024
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- The Board and Management of TransCode Therapeutics (NASDAQ: RNAZ) today issued the following open letter to shareholders of the Company: Dear Shareholder, As you may have seen, [...]
Biomerica Announces inFoods® IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024
13/05/2024
With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th most common diagnosis [...]
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
13/05/2024
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FRANCISCO, Calif., [...]

Pages